AcelRx Pharmaceuticals Inc (ACRX)

3.20
0.09 2.70
NASDAQ : Health Care
Prev Close 3.29
Open 3.30
Day Low/High 3.20 / 3.31
52 Wk Low/High 2.40 / 5.88
Volume 87.41K
Avg Volume 357.60K
Exchange NASDAQ
Shares Outstanding 45.31M
Market Cap 145.45M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics

AcelRx Publishes A Review Of Hospital-Based Opioid Patient-Controlled Analgesia, Risks And Pharmacoeconomics

- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy -

First Week of ACRX September 16th Options Trading

First Week of ACRX September 16th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery

Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations

AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones

AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones

- ARX-04 ER and Postoperative Study Results, NDA Submission

AcelRx Pharmaceuticals Conducts Pre-NDA Meeting With U.S. Food And Drug Administration For ARX-04

AcelRx Pharmaceuticals Conducts Pre-NDA Meeting With U.S. Food And Drug Administration For ARX-04

- AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting

AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting

Presentation of Clinical Data from Recently Completed Phase 3 Study in Ambulatory Surgery Patients Highlights Efficacy and Tolerability of ARX-04 30 mcg